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Introduction {#sec1}
============

Ovarian cancer (OC) is the most lethal gynecological cancer. In more than 80% of patients, the disease is not discovered until advanced stage and metastasis ([@bib33]). After primary debulking surgery and adjuvant chemotherapy, 70%--80% of the patients show tumor relapse with increasing chemoresistance ([@bib37]). Most OC cases display an epithelial phenotype (epithelial OC \[EOC\]), with 75% of the patients diagnosed with high-grade serous OC (HGSOC) of FIGO stage III or IV (i.e., showing extensive metastatic spread) ([@bib23]). HGSOC causes up to 80% of the mortality among OC patients, and thus represents the most outstanding clinical challenge in gynecological oncology. Etiology and site of origin of EOC, whether it is ovarian surface epithelium (OSE) or fallopian tube epithelium (FTE) (or both), are still under intense debate ([@bib25]).

Mechanisms underlying EOC pathobiology are poorly understood, and therapeutic efficiency and patient survival are not significantly improving ([@bib49]). Most studies have been done using cancer cell lines that perform poorly in recapitulating histopathological and molecular phenotype of the tumor of origin and of EOC nature in general, thereby lacking clinical translatability ([@bib29]). Patient tumor-derived xenografts, growing in immune-deficient mice, better mimic the original tumor but their establishment is inefficient, lengthy, and costly, and is ethically questionable ([@bib39]). Therefore, more appropriate experimental and preclinical EOC models are needed.

A powerful research tool to model and study human cancer *in vitro* is provided by the innovative organoid technology. Organoids represent *in vitro* self-developing three-dimensional (3D) tissue reconstructions, reproducing key features of the tissue of origin ([@bib9]). In recent studies it has been demonstrated that organoids can be developed from multiple divergent cancer types such as colon, prostate, breast, and endometrial cancer. These tumor-derived organoids maintain type- and patient-specific characteristics ([@bib5], [@bib15], [@bib40], [@bib11]). To derive organoids, patients' tumor biopsies are dissociated into fragments and cells, embedded in a 3D extracellular matrix scaffold (such as Matrigel), and cultured in a cocktail of growth and signaling factors, which must be defined and optimized for each individual cancer type.

In the present study, we established organoids from OC that recapitulate disease and patients' tumor characteristics. Our study independently confirms and expands the recent report by [@bib26], although overall derivation efficiency is lower. Importantly, it adds new developed organoid lines to the growing OC organoid biobank, which is an essential impetus to enable the deciphering of the cancer\'s complex nature, pathogenesis, therapy resistance, and drug sensitivity, and to move the field forward toward more efficient (patient-tailored) treatments.

Results {#sec2}
=======

Establishing Expandable Organoids from EOC {#sec2.1}
------------------------------------------

EOC biopsies (predominantly HGSOC; [Table 1](#tbl1){ref-type="table"}) were dissociated and cells seeded in OC organoid culture medium-1 (OCOM1; [Table S1](#mmc1){ref-type="supplementary-material"}), the composition of which was based on the medium previously defined to derive organoids from endometrium and endometrial cancer ([@bib4], [@bib5]). However, organoid development efficiency was low (33%) and expandability was limited to 1--2 passages ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). Therefore, we systematically tested culture medium components to improve EOC organoid establishment and growth. Reducing the concentration of the transforming growth factor β (TGFβ) pathway inhibitor A83-01, raising the level of nicotinamide, and changing the source of RSPO1 from cell line-conditioned medium to recombinant protein (culture medium referred to as OCOM2; [Figure S1](#mmc1){ref-type="supplementary-material"}A and [Table S1](#mmc1){ref-type="supplementary-material"}) increased the expandability of developed organoid lines (to 3--7 passages; data not shown) but did not improve formation efficiency ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). Further modification of the medium involving (1) omission of basic fibroblast growth factor (bFGF) and FGF10, (2) addition of insulin-like growth factor 1 (IGF1) and hepatocyte growth factor (HGF), known to stimulate growth of OC cell lines ([@bib2]), and (3) reduction of the p38 mitogen-activated protein kinase inhibitor (p38i) SB203580 (OCOM3; [Figure S1](#mmc1){ref-type="supplementary-material"}A and [Table S1](#mmc1){ref-type="supplementary-material"}), shown to be beneficial for establishing organoids from other cancer types such as endometrial and breast cancer ([@bib5], [@bib40]), improved formation efficiency ([Figure S1](#mmc1){ref-type="supplementary-material"}A and S1B) but did not further increase expandability (data not shown). TGFα, reported to induce cell proliferation in cancerous OSE ([@bib43]), did not advance organoid growth initiation (data not shown), while RSPO1 was found to be essential ([Figure S1](#mmc1){ref-type="supplementary-material"}B; comparable with [@bib26] and [@bib20]). Finally, we found that addition of NRG1 (OCOM4; [Figure S1](#mmc1){ref-type="supplementary-material"}A and [Table S1](#mmc1){ref-type="supplementary-material"}) significantly increased the number of organoids formed ([Figure S1](#mmc1){ref-type="supplementary-material"}C), thereby independently (without prior knowledge) confirming, and in addition quantitatively supporting, the recent finding by [@bib26]. This beneficial effect of NRG1 is also in line with previous studies showing a potential (paracrine) growth-stimulatory effect of NRG1 in OC tumors and cell lines ([@bib17], [@bib43]). We further zoomed in on the effect of NRG1 and found a significant increase in the number of proliferating (Ki67^+^) cells in the organoid cultures as well as of the size of the organoids ([Figure S1](#mmc1){ref-type="supplementary-material"}D). Taken together, by thoroughly probing multiple medium components, we eventually defined a culture medium (OCOM4) that strongly enhanced the EOC organoid formation efficiency (from 33% to 56%; [Figure S1](#mmc1){ref-type="supplementary-material"}A). Interestingly, addition of NRG1 also increased the passageability of the EOC-derived organoids ([Figure S1](#mmc1){ref-type="supplementary-material"}E). Although the number of organoids formed at tumor seeding (passage 0 \[P0\]) in OCOM4 was not inferior to the culture medium used in [@bib26] ([Figure S1](#mmc1){ref-type="supplementary-material"}F; "Kopper" medium, see [Table S1](#mmc1){ref-type="supplementary-material"}), overall organoid derivation efficiency over total number of patients remained lower (for a detailed comparison, see [Table S2](#mmc1){ref-type="supplementary-material"}). Possible reasons are described in the [Discussion](#sec3){ref-type="sec"}. Of note, organoid formation efficiency did not significantly differ between freshly obtained and cryopreserved biopsies ([Figure S1](#mmc1){ref-type="supplementary-material"}G and [Table 1](#tbl1){ref-type="table"}), thereby underscoring the possibility to store clinical samples pending organoid establishment (as described for some other cancers, in particular mouse xenograft and human breast tumors; [@bib52]). Furthermore, organoids could be derived from EOC biopsies of both chemo-naive patients (obtained by primary debulking surgery) and chemotherapy-treated patients (obtained by interval debulking surgery after prior neoadjuvant chemotherapy) ([Figure S1](#mmc1){ref-type="supplementary-material"}G).Table 1Overview of EOC Patients and Samples and of Established Organoid LinesPatient/EOC Sample No.Fresh/CryoEOC Type[a](#tblfn1){ref-type="table-fn"}Patient Treatment[b](#tblfn2){ref-type="table-fn"}EOC Organoid Line[c](#tblfn3){ref-type="table-fn"}Organoid MorphologyPassaging Time1freshmalignant mixed mesonephric tumor IC2PDS--2freshHGSOC IVAIDS--3freshHGSOC IVBPDSEOC-O_1cystic/low-cohesiveshort-term4freshHGSOC IIICIDSEOC-O_2dense/cysticlong-term5freshHGSOC IIICIDS--6freshHGSOC IVBIDS--7freshHGSOC IIICIDS--8cryoHGSOC IVBIDS--9freshLGSOC IVBIDSEOC-O_3dense/low-cohesiveshort-term10freshHGSOC IVBTDSEOC-O_4denselong-term11cryoHGSOC IIICPDS--12freshHGSOC IIICIDS--13AfreshHGSOC IVB (omentum)IDS--13BcryoHGSOC IVB (ovary)IDSEOC-O_5denseshort-term14freshclear cell ovarian cancer IIIA1(i)PDSEOC-O_6dense/cysticshort-term15cryoHGSOC IVBIDSEOC-O_7cysticlong-term16cryoHGSOC IVBIDS--17cryoHGSOC IIIBSDS--18freshHGSOC IIICIDSEOC-O_8low-cohesivelong-term19freshHGSOC IVBIDS--20freshHGSOC IVBIDS--*21A*[d](#tblfn4){ref-type="table-fn"}*freshHGSOC IIIC (ovary)IDSEOC-O_9cysticlong-term*21BfreshHGSOC IIIC (omentum)IDS--21CfreshHGSOC IIIC (rectum)IDS--22cryomucinous cystadenocarcinoma IC1PDSEOC-O_10cysticshort-term23AcryoHGSOC IVB (ovary)PDSEOC-O_11cysticlong-term23BcryoHGSOC IVB (omentum)PDS--24cryoHGSOC IVBIDSEOC-O_12denseshort-term25cryoHGSOC IIICIDS--26cryoLGSOC IIICPDSEOC-O_13dense/low-cohesiveshort-term27cryoHGSOC IIBPDS--[^1][^2][^3][^4]

In the culture conditions as optimized above, EOC-derived organoids typically developed within 2--4 weeks, at a rate varying in accordance with individual patients' tumors ([Figure 1](#fig1){ref-type="fig"}A). Organoid morphology also differed between patients' EOC samples, displaying either a dense phenotype with no or only small lumen, a disorganized configuration of low cellular cohesiveness ("low-cohesive"), or a cystic phenotype with a (single) cell layer bordering a large lumen ([Figure 1](#fig1){ref-type="fig"}B; comparable with [@bib26]). The different organoid types all showed substantial proliferative activity (Ki67^+^; [Figure 1](#fig1){ref-type="fig"}B) and could be expanded, either short-term (up to 4 passages) or long-term (more than 4 passages, up to 1 year and more) ([Figure 1](#fig1){ref-type="fig"}C and [Table 1](#tbl1){ref-type="table"}). Although the overall efficiency of establishing organoids from HGSOC patients was lower than that in [@bib26], the percentage of long-term passageable organoids among the established lines was comparable (see [Table S2](#mmc1){ref-type="supplementary-material"}). The organoids retained their proliferative activity in later passages without any signs of decreased cell viability (as assessed by immunostaining for the apoptosis marker cleaved-caspase 3; [Figure S1](#mmc1){ref-type="supplementary-material"}E). All organoid lines established were cryopreserved and biobanked ([Table 1](#tbl1){ref-type="table"}).Figure 1Establishing Organoid Cultures from Ovarian Cancer(A) Organoid development from EOC (passage 0, P0), showing patients' tumor-associated differences in growth rate. Representative bright-field images are shown at different days (D) after seeding. Scale bars, 200 μm.(B) Distinct morphology of patients' EOC organoid lines. Representative images of organoid culture and individual organoids (bright-field), of H&E staining, and of Ki67 immunofluorescence analysis (DAPI as nuclear stain) are shown. Some high-grade nuclear atypia are indicated by arrows. Bar graph (right) depicts the proportion of Ki67^+^ cells in the organoid lines as indicated (mean ± SEM, n = 3--5 independent experiments per line). Scale bars, 200 μm unless indicated otherwise.(C) Long-term expansion of EOC organoid lines. Representative bright-field images of different passages (P) are shown. Scale bars, 200 μm.

EOC-Derived Organoids Reproduce Disease and Original Tumor Phenotype {#sec2.2}
--------------------------------------------------------------------

First, histological (hematoxylin-eosin \[H&E\]) analysis was performed showing high-grade nuclear atypia in the primary tumor samples as characteristic for EOC (particularly HGSOC) ([Figures 2](#fig2){ref-type="fig"}A, 2B, and [S2](#mmc1){ref-type="supplementary-material"}A). High-grade nuclear atypia were also observed in the EOC-derived organoids ([Figures 1](#fig1){ref-type="fig"}B, [2](#fig2){ref-type="fig"}A, 2B, and [S2](#mmc1){ref-type="supplementary-material"}A). Moreover, multinucleated giant cells found in the primary tissue were also present in the corresponding organoids ([Figure S2](#mmc1){ref-type="supplementary-material"}A; EOC-O_8). Second, epithelial markers (cytokeratin 8 \[CK8\], CK18, E-cadherin) were positive in the primary tumor and prominently expressed in the organoids, thereby demonstrating their (tumor) epithelial nature as typical for organoid models ([Figures 2](#fig2){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}B; [Table 2](#tbl2){ref-type="table"}) ([@bib39]). Third, expression of the HGSOC markers PAX8 ([@bib18], [@bib53]) and CK7 ([@bib8]) was observed in primary tumor, which was effectively recapitulated in the organoids ([Figure 2](#fig2){ref-type="fig"}A and [Table 2](#tbl2){ref-type="table"}). The tumor-suppressor protein p53 is often mutated in HGSOC ([@bib47]) and the p53 immunostaining profile is used for pathological diagnosis. The aberrant p53 overexpression pattern (i.e., intense nuclear staining) in primary tumors was mirrored in corresponding organoid lines ([Figure 2](#fig2){ref-type="fig"}B and [Table 2](#tbl2){ref-type="table"}). Also, complete absence of p53 immunostaining ("null pattern") in the primary tumor was recapitulated in the derived organoids ([Figure 2](#fig2){ref-type="fig"}B, EOC-O_12; [Table 2](#tbl2){ref-type="table"}). The expression profile of estrogen receptor α (ERα) and progesterone receptor (PR), clinically variable in HGSOC ([@bib51]), was also retained in the corresponding organoid lines ([Figure 2](#fig2){ref-type="fig"}A and [Table 2](#tbl2){ref-type="table"}). Finally, we performed additional immunohistological and immunofluorescence analyses on organoid lines for which no or insufficient primary tissue was available, and found expression of the HGSOC markers ([Figure S2](#mmc1){ref-type="supplementary-material"}C and [Table 2](#tbl2){ref-type="table"}).Figure 2EOC-Derived Organoids Capture Disease and Primary Tumor Phenotype(A) Organoids reproduce the primary tumor\'s molecular and cellular phenotype. Representative pictures of H&E staining and immunostaining of disease-associated protein markers in primary tumor and organoids are shown (DAPI and hematoxylin as nuclear stain). The primary tissue shows abundant high-grade nuclear atypia (H&E), which are also found in the organoids (some indicated with arrows). Scale bars, 200 μm.(B) Organoids reproduce the primary tumor\'s p53 phenotype. Representative pictures of H&E staining and p53 immunostaining in primary tumor and organoids are shown (DAPI and hematoxylin as nuclear stain). The primary tissue shows abundant high-grade nuclear atypia (H&E), which are also found in the organoids (some indicated with arrows). Scale bars, 200 μm.(C) Organoids show EOC (HGSOC)-associated gene expression profile. Heatmap of expression of genes, as quantified by qRT-PCR and presented as relative expression to *GAPDH* (ΔC~t~) (visualized as color-coded row *Z* score), in organoids from different patients (with different morphology) is shown. Colors range from blue (low expression) to yellow (high expression).(D) *ERBB* expression profile in primary tumors (EOC-T) and corresponding organoids (EOC-O) as quantified by qRT-PCR and presented as relative expression to *GAPDH* (ΔC~t~), visualized as color-coded row *Z* score. Colors range from blue (low expression) to yellow (high expression).(E) Organoids capture the mutational profile of the primary tissue. Representative copy-number profiles from three different organoid lines (analyzed at P2--P4) and corresponding primary EOC tumor are shown. Numbers indicate ploidy (P) and tumor cell fraction (T%).(F) Venn diagrams presenting the number of genetic aberrations (subs, substitutions; indel, insertion/deletion) that are common (intersection) or different between primary tumor and corresponding organoids. Numbers were retrieved from [Table S3](#mmc2){ref-type="supplementary-material"}.(G) Mutation matrix representing hits in cancer consensus, OC-relevant, homology recombination, and amplification-driver genes as detected by WES in primary tumor and derived organoids. P, primary tumor; O, organoids.Table 2Overview of Immunohistochemical and Immunofluorescent Analysis of HGSOC-Derived OrganoidsE-cadherinCK8/CK18PAX8CK7p53ERαPREOC-O_4++++++/−+EOC-O_7[a](#tblfn5){ref-type="table-fn"}++++−+/−+EOC-O_8++++++/−+/−EOC-O_11+++++/−−+/−EOC-O_12++++−−+[^5][^6]

Next, we analyzed in organoid lines of different patients/morphology the gene expression of multiple markers known to be highly or lowly expressed in HGSOC ([Figure 2](#fig2){ref-type="fig"}C). Organoids showed prominent expression of *CD9*, *CK19*, and *HE4*, the latter being one of the most frequently upregulated genes in EOC ([@bib22], [@bib59]). In contrast, expression levels of *CK20* and *ERβ* (which is highly expressed in normal OSE; [@bib28]) were very low to absent, typical characteristics of EOC ([@bib8], [@bib51]). *PAX2*, an FTE transcription factor that is lost in 85% of EOC ([@bib18]), was undetectable in the HGSOC organoid lines ([Figure S2](#mmc1){ref-type="supplementary-material"}D). We also analyzed the expression of the *ERBB* receptor family through which NRG1 acts ([@bib19]). Interestingly, *ERBB2* and *ERBB3* are highly expressed in the organoids, and expression of *ERBB3*, one of the cognate receptors of NRG1, is predominantly enriched in comparison with the primary tumor ([Figure 2](#fig2){ref-type="fig"}D). The role and clinical significance of ERBB2 (HER2) and ERBB3 (HER3) in OC remain unclear and controversial. The new EOC organoid models provide experimental tools to revive this field (see [Discussion](#sec3){ref-type="sec"}). Comparison of *ERBB* receptor expression in organoids developed with and without NRG1 (OCOM4 and OCOM3, respectively) suggests that the final optimized NRG1-containing culture conditions do not select for an NRG1-dependent (ERBB-expressing) subset among EOC types, since organoids grown in medium without NRG1 (i.e., OCOM3) showed *ERBB* expression levels similar to those of organoids grown in OCOM4 ([Figure S2](#mmc1){ref-type="supplementary-material"}E).

Taken together, patients' EOC-derived organoids reproduce the disease\'s cellular and molecular phenotype and show atypia and protein marker expression as present in the original tumor.

Patient EOC-Derived Organoids Recapitulate Genomic and Mutational Landscape of the Primary Tumor {#sec2.3}
------------------------------------------------------------------------------------------------

We investigated whether the organoid lines also recapitulated the genetic make-up of their parent tumor. Low-coverage whole-genome sequencing revealed that the vast majority of somatic copy-number alterations (SCNA) in primary tumors were retained in the corresponding organoid lines ([Figure 2](#fig2){ref-type="fig"}E). These data also allowed to bioinformatically evaluate tumor content of primary biopsy and derived organoids, showing a clear enrichment and high tumor purity in the organoids ([Figure 2](#fig2){ref-type="fig"}E). Prominent SCNA were also observed (using array comparative genomic hybridization \[array CGH\]) in other organoid lines (for which primary tissue was not available; [Figure S2](#mmc1){ref-type="supplementary-material"}F), thereby demonstrating their chromosomally aberrant nature with multiple gains or losses as frequently observed in HGSOC ([@bib27], [@bib47]) and as found here ([Figure 2](#fig2){ref-type="fig"}E). Immunostaining analysis of mutant p53 also supported the major tumor content of these organoid lines ([Figure S2](#mmc1){ref-type="supplementary-material"}F). SCNA present in the primary tissue of EOC-O_9 were not retrieved in the derived organoid culture ([Figure S2](#mmc1){ref-type="supplementary-material"}F), indicating that these organoids developed from non-cancerous epithelial cells present in the biopsy, which overtook the culture (as previously also reported for other cancer-derived organoids; [@bib5], [@bib15], [@bib11], [@bib56]), further supported by normal-cell histology (round, polarized) of the organoids and the absence of nuclear atypia and nuclear p53 expression, the latter being present in the primary tissue ([Figure S2](#mmc1){ref-type="supplementary-material"}F). Expression of PAX8 and acetylated α-tubulin point to an FTE origin of this organoid line ([Figure S2](#mmc1){ref-type="supplementary-material"}F; [@bib24], [@bib26]).

Next, several tumors from patients' wild-type for germline *BRCA1* (as retrieved from the patients' pathology reports) were sequenced at the exome base-pair level using whole-exome sequencing (WES), together with the derived organoids. The vast majority (98%) of the genetic alterations detected (i.e., 1,638) were similarly present in both primary tumor and resultant organoid line ([Figure 2](#fig2){ref-type="fig"}F and [Table S3](#mmc1){ref-type="supplementary-material"}). In particular, mutations in cancer consensus genes ([@bib45]), in OC-relevant genes (i.e., genes mutated in \>4% of OC; [@bib14]) and in the homologous recombination pathway ([@bib36]) were identified, which highly corresponded between tumor and organoids ([Figure 2](#fig2){ref-type="fig"}G and [Table S3](#mmc1){ref-type="supplementary-material"}). For instance, we found frameshift or non-synonymous mutations in the tumor-suppressor genes *CREBBP*, *FOXO1*, *PRKAR1A*, and *CHEK2* ([@bib50], [@bib54], [@bib55], [@bib58]), identically in primary tumor and derived organoids. Non-synonymous substitutions in the nuclear transport protein *XPO1*, which regulates export of tumor suppressors, cell-cycle inhibitors, and oncogenes ([@bib3]), were similarly observed in both tumor and organoids. A non-frameshift insertion and deletion were detected in the key cancer/OC-associated genes *BRAF* and *NOTCH1*, respectively, identically in tumor and corresponding organoids. The loss of three mutations in EOC-O_11 organoids ([Figure 2](#fig2){ref-type="fig"}G) may point to a selection of (a) subclone(s) in this particular organoid line (as also reported for other cancer-derived organoids; [@bib5], [@bib6]). Finally, focal or whole-region amplification, as being propelled by central driver genes (*MYC*, *MECOM*, *NOTCH3*, *CCNE1*), was similarly present in tumor and corresponding organoid line ([Figure 2](#fig2){ref-type="fig"}G). Of note, WES confirmed the *BRCA1* wild-type genotype of the patients/samples analyzed (as prospectively retrieved from the patients' reports) and also showed a *TP53* wild-type genotype (which, retrospectively, was in agreement with the patients' reports). Developing long-term expandable organoids from patients with high-risk OC predisposition due to a germline *BRCA1* mutation ([@bib1]) ([Figure S2](#mmc1){ref-type="supplementary-material"}G) provides new *in vitro* research models that should allow us to investigate the role and impact of *BRCA1* mutation in OC progression.

Taken together, the developed patients' EOC-derived organoids highly recapitulate the genomic constitution of the primary tumor.

EOC-Derived Organoids Show Tumor-Specific Sensitivity to Clinically Used Chemotherapy {#sec2.4}
-------------------------------------------------------------------------------------

To explore the potential of the EOC-derived organoids for *in vitro* drug screening applications, we tested the effect of several chemotherapeutic agents standardly used in the clinic to treat HGSOC (i.e., paclitaxel, carboplatin, doxorubicin, and gemcitabine) on established EOC organoids. Drug-response curves revealed distinct sensitivities of the different organoid lines for the drugs ([Figure 3](#fig3){ref-type="fig"}), thereby indicating patients' tumor-dependent responses, and at the same time exposed distinct efficacies of the different drugs on individual tumor organoid lines ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Also, nutlin-3 (currently tested as a targeted therapeutic agent for *TP53* wild-type EOC in preclinical settings; [@bib57]) showed different activity depending on the patient's tumor, and more in particular on the p53 status. EOC-O_7 organoids, derived from a *TP53* wild-type tumor (information retrieved from the patients' pathology report), is sensitive to nutlin-3 ([Figure S3](#mmc1){ref-type="supplementary-material"}B). In contrast, EOC-O_4 and EOC-O_8 organoids, established from *TP53* mutant tumors ([Figures 2](#fig2){ref-type="fig"}B and [S2](#mmc1){ref-type="supplementary-material"}F; corresponding to the patient pathology reports) showed resistance to nutlin-3 ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Together, our tests show the potential applicability of EOC-derived organoids for drug screening (see also [@bib26]).Figure 3EOC-Derived Organoids Show Patient-Specific Drug ResponsesDose-response curves of EOC organoid cultures from different patients treated for 72 h with drugs are shown. Cell viability was measured using XTT assay. Mean data points (n = 3 biologically independent experiments, i.e., independent donors, with each dot representing the mean of three technical replicates per donor) are displayed for each drug concentration analyzed. IC~50~ values are determined (dashed lines) and indicated.

Discussion {#sec3}
==========

In the present study, we established organoids from patients' EOC (predominantly HGSOC). EOC organoid derivation was not negatively influenced by prior cryopreservation of the clinical biopsy, enabling sample collection and storage pending organoid establishment (as also described for some other cancers, in particular mouse xenograft and human breast tumors; [@bib52]). We found that NRG1 exerts a beneficial effect on EOC organoid development and growth, including increased proliferative activity. Our data, together with the recent findings of [@bib26], support an important impact of NRG1 on OC growth ([@bib17], [@bib43]) and may provide hints toward NRG1-targeted treatment prospects ([@bib12]). In particular, we found high expression of *ERBB2* (HER2) in tumors and organoids, and high, enriched expression of *ERBB3* (HER3) in the organoids. NRG1 acts through ERBB3 (and/or ERBB4), which heterodimerizes with ERBB2 ([@bib19]). The role and clinical significance of HER2 in OC, in contrast to its proven importance in breast cancer, remain unclear and controversial ([@bib42]). A recent meta-analysis revealed a potential prognostic value, although no association was found for serous OC ([@bib30]). Early preclinical studies have defined HER2 as a potential therapeutic target in OC, but have not extensively been followed up nor translated into clinical practice, particularly because the tested HER2-targeted agents failed to show a significant response ([@bib44]). More recent studies suggest that targeting HER2 (e.g., using trastuzumab) sensitizes OC to chemotherapy ([@bib19], [@bib44]). Given the success of targeting HER2 in breast and gastric cancer, continuing efforts are recommended regarding HER2 in OC, which can now be explored using the EOC organoid models. Also, the role and significance of ERBB3/HER3 (being one of the cognate receptors of NRG1) in OC remain to be determined. HER3 expression might be associated with worse survival in OC, particularly when HER2 is concomitantly overexpressed ([@bib35]). A recent study revealed an activated NRG1/ERBB3 pathway in OC cell lines (*in vitro* and as xenograft *in vivo* which, however, showed distinct death or proliferation-block responses), and in a significant fraction (\~30%) of patients' advanced-stage OC (as studied using tumor cells from ascites) ([@bib43]). Similar to HER2, targeting HER3 may also potentiate the effect of chemotherapy ([@bib7]). The EOC organoid models, developed here and in other studies, may revive this domain to decipher the role, impact, and targetability of the NRG1/ERBB2/ERBB3 pathway in OC. Moreover, patient-derived EOC organoids may help to predict individual patient responses and identify the OC patients who may benefit from NRG1/ERBB2/ERBB3-oriented therapy.

Although the initial development of organoids from the tumor biopsy is comparable in our optimized culture medium OCOM4 and the Kopper medium, overall derivation efficiency is lower than in [@bib26]. Several variables may account for this difference, including patient group variability and heterogeneity (e.g., not covering identical geno-/phenotypes) and biopsy variability (e.g., regarding quality/necrosis, size, tumor abundance). Furthermore, differences in medium components (such as hydrocortisone and forskolin) may, although not affecting the organoid number at initiation, still be important to enhance the efficiency of kick-starting organoid cultures from individual patients. Extensive comparison with the culture conditions of other recent OC organoid studies ([@bib20], [@bib32]) was not performed.

Despite the now well-demonstrated capacity to establish organoids from EOC, more studies are required to enhance the derivation efficiency (as is also true for other cancer-derived organoids; [@bib5], [@bib15]), in particular by scrutinizing and fine-tuning culture conditions to eventually capture more patients and geno-/phenotypes. Although still unsettled and controversial, HER2 overexpression may be present in 10%--30% of all OC types and 20%--40% of HGSOC (which may be higher in advanced stages) ([@bib19]), and HER3 is reported to be expressed in a widely divergent range (from 3% to 90%) of all OC ([@bib10]) and an estimated 20% of serous OC ([@bib38]). It could be possible that our culture conditions (probably also true for [@bib26]) capture the establishment of organoids from NRG1-dependent (i.e., ERBB-expressing) subtypes of EOC. Although we provide supportive data that the finally optimized culture condition containing NRG1 does not select for NRG1-dependent (ERBB-expressing) OC types, we cannot exclude that initial organoid formation may occur under the influence of endogenous NRG1 (thus indeed thriving ERBB-expressing samples), with exogenous NRG1 enhancing the efficiency by increasing the number of organoids.

The established EOC-derived organoids capture disease cellular characteristics (high-grade nuclear atypia) and molecular phenotype (marker expression). Interestingly, mucin 16 (*MUC16*) was also found to be expressed in the organoids, and non-synonymous substitutions in *MUC16* were similarly observed in both tumor and organoids. *MUC16* encodes for cancer antigen 125 (CA-125), which is not detectable in normal OSE and is therefore used as a biomarker during advanced-stage OC follow-up ([@bib48]), although its significance remains highly controversial ([@bib46]). Moreover, we found that nuclear atypia, protein marker expression, and SCNA and mutational profile of the tumors was highly conserved in the corresponding organoids although occasional deviations were observed, which may be due to presence of non-tumor cells in the DNA-extracted primary tissue and/or the selection and growth of (a) specific mutant subclone(s) in the culture conditions used (as also reported for other cancer types; [@bib5], [@bib6], [@bib11]). Subclone selection might also match what is happening in the patient\'s cancer at recurrences during consecutive therapies (e.g., selection of the more dominant or chemoresistant subclone\[s\]). On the other hand, new mutations arising in the organoids might mimic the "natural" mutational evolution of the cancer (being propelled by cancer driver genes such as MYC) ([@bib5]).

We found that organoids can also be established from EOC tumor cells remaining after chemotherapy. Chemoresistant cells may represent cancer stem cells postulated to drive OC resistance and recurrence ([@bib16]). The (cancer) stem cell markers *ALDH1A1* and *LGR5* were found to be expressed in some of the organoid lines analyzed. Of note, OSE and FTE contain cells expressing LGR5, which has been suggested to contribute to EOC development ([@bib34]).

Finally, we demonstrated that the EOC-derived organoids are amenable to drug screening and show differential sensitivity of individual patient organoid lines to the chemotherapeutic agents tested. Hence, by predicting patients' tumor responses to specific drugs using the organoids as "avatars," the optimal treatment for the individual patient may be selected (as recently reported for other cancer types; [@bib6], [@bib21], [@bib40], [@bib11]). Moreover, the EOC organoid models will be highly instrumental in moving into the field of immunotherapy (e.g., using CAR-T and natural killer cells), as has recently been shown for colorectal cancer organoids ([@bib41]). Since organoids are typically composed of the epithelial compartment of the original tissue, further perfecting the model by adding stromal and immune components of the tumor microenvironment will eventually be needed to reach the organoid model\'s full potential.

In summary, we established organoid lines from patient-derived EOC that capture disease and patients' tumor diversity and hallmarks, thereby adding new lines to the existing EOC organoid repertoire, which is essential for gaining deeper insight into the cancer\'s etiology, pathogenesis, heterogeneity, and chemoresistance, and for identifying new therapeutic targets and screening new drugs, preferably in a patient-tailored manner (also reviewed in [@bib31]). It should be acknowledged that the EOC organoid derivation protocol still deserves further efforts for improvement. The EOC organoid platform has strong potential as an experimental and preclinical research model, and in particular as impetus to revive NRG1/ERBB research in OC, and may eventually identify response-predictive biomarkers, assist in clinical decision making, and provide personalized therapeutic options, particularly for patients in whom standard clinical routes have been exhausted.

Experimental Procedures {#sec4}
=======================

Detailed methods are provided in [Supplemental Information](#app1).

Establishing Organoid Cultures from Patient-Derived EOC Biopsies {#sec4.1}
----------------------------------------------------------------

EOC biopsies were obtained from patients following standard primary or interval debulking surgery ([Table 1](#tbl1){ref-type="table"}). The study was approved by the Ethical Committee Research UZ/KU Leuven (S60589), and written informed consent was obtained from all participating patients. The freshly obtained or cryopreserved tissue was dissociated using collagenase type IV and mechanical shearing. Cells were plated in 70% growth factor-reduced Matrigel/30% Dulbecco's modified Eagle's medium/F12 and cultured in defined media ([Table S1](#mmc1){ref-type="supplementary-material"}), and organoids were passaged between 2 and 4 weeks after seeding.

Immunohistochemical Analysis {#sec4.2}
----------------------------

Tissues and organoids were fixed in paraformaldehyde and paraffin-embedded sections subjected to H&E, immunohistochemical, and/or immunofluorescence staining (for antibodies, see [Supplemental Information](#app1)). Microscopy pictures were taken and proportions of immunoreactive cells counted using Fiji software (<http://imagej.net/Citing>).

Genomic Analysis {#sec4.3}
----------------

For array comparative genomic hybridization (array CGH), genomic DNA from organoids and primary tissues was labeled with Cy5 and hybridized to Cy3-labeled sex-matched reference DNA. Arrays were scanned using an Agilent microarray scanner, followed by calculation of signal intensities using Agilent Feature Extraction software.

Sequencing was performed on whole-exome and low-coverage whole-genome DNA libraries by Illumina\'s NextSeq and HiSeq4000, respectively ([Table S4](#mmc1){ref-type="supplementary-material"}). Raw sequencing reads were aligned to the human reference genome and copy-number variations were identified using the low-coverage whole-genome sequencing data while variants were identified in the whole-exome data and further filtered and annotated to retain somatic mutations, using in-house developed bioinformatics pipelines. Tumor content and corresponding ploidy was quantified with ASCAT.

Targeted Sanger Sequencing {#sec4.4}
--------------------------

The targeted PCR-amplified *BRCA1* gene region (for primers, see [Table S5](#mmc1){ref-type="supplementary-material"}) was purified and Sanger sequenced by Eurofins Genomics (Ebersberg, Germany).

Gene Expression Analysis {#sec4.5}
------------------------

Organoid RNA was reverse transcribed and subjected to quantitative real-time PCR (qPCR) using gene-specific forward and reverse primers ([Table S5](#mmc1){ref-type="supplementary-material"}). Expression levels were normalized to expression of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*). Relative gene expression levels were calculated as ΔC~t~ values (C~t~ "target gene" minus C~t~ "*GAPDH*"), and the corresponding heatmap was generated by Heatmapper (<http://www2.heatmapper.ca/expression/>).

Drug Screening {#sec4.6}
--------------

Organoid cultures were treated with a concentration series of paclitaxel, carboplatin, doxorubicin, gemcitabine, or nutlin-3. Cell viability was assayed after 72 h using the XTT assay, and data analysis was performed with GraphPad Prism.

Statistical Analyses {#sec4.7}
--------------------

Statistical analyses were performed using GraphPad Prism and are specified in the figure legends. Statistical significance was defined as p \< 0.05. All experiments were performed with ≥3 biological replicates unless otherwise indicated.
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[^1]: HGSOC, high-grade serous ovarian cancer; LGSOC, low-grade serous ovarian cancer. In case of additional out-of-the-ovary sampling from the same patient, the different surgical sites are specified.

[^2]: IDS, interval debulking surgery; PDS, primary DS; SDS, secondary DS; TDS, tertiary DS.

[^3]: --, no organoid derivation.

[^4]: Eventual healthy tissue organoids.

[^5]: +, positive; +/−, some positive cells; −, no positive cells.

[^6]: Data not shown.
